A 26-week oral toxicity and micronucleus assays of the new cardioprotective drug stobadine (CAS 95751-51-2), in the form of dipalmitate salt (DP 1031) were performed in Wistar rats of both sexes. DP 1031 was administered daily orally in doses of 7.07, 23.60 and 70.07 mg/kg. Physical appearance and general behaviour of the treated animals were normal, with a small deviation (hypoactivity in the highest dose group at the start of experiment). Food and water consumption as well as body weight gain exhibited similar values in the control and experimental groups of animals. No drug-related changes were noted in the haematological, biochemical, histopathological and genotoxicological examinations. Neither sex differences nor dose-related changes were noted under these conditions.